# Guy P. Nohra

> Guy P. Nohra is a Series B investor at Alta Life Sciences backing Health Care and Biotechnology. See 9 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Alta Life Sciences](https://shizune.co/investors/profile/alta-life-sciences)
- Location: Palo Alto, United States
- Total investments: 9
- Last investment: Jun 2019
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/guy-paul-nohra/56/2a0/836

Guy P. Nohra is a Series B investor at Alta Life Sciences in Palo Alto focused on Health Care and Biotechnology. Guy is a Managing Director of Alta Partners, and was also a partner at Burr, Egan, Deleage & Co., which he joined in 1989. Guy has been involved in the funding and development of notable medical technology and life science companies including Cutera, Innerdyne, R2 Technology, deCODE genetics, and Vesica.Previously, Guy was Product Manager ofMedical Products with Security Pacific Trading Corporation. He was responsible for a multi-million dollar product line and traveled extensively in Korea, Taiwan, Hong Kong, China and Southeast Asia.Currently, Guy serves on the board of directors of several private companies, including AcelRx, ATS Medical, Carbylan Biosurgery, Coapt Systems, Paracor Medical, PneumRx and Vertiflex, and is the Chairman of the Board of USGI Medical. He also serves on the board of directors of the Medical Device Manufacturing Association (MDMA). He was recently named to the Forbes "Midas List" of dealmakers in high-tech and life sciences. Guy also serves as the President of the Silicon Valley chapter of The Leukemia and Lymphoma Society.He holds a Master of Business Administration from the University of Chicago and a Bachelor of Arts in History from Stanford University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 44% |
| Biotechnology | 3 | 33% |
| Medical Device | 3 | 33% |
| Medical | 2 | 22% |
| Hospital | 1 | 11% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 33% |
| Series A | 2 | 22% |
| Funding Round | 2 | 22% |
| Series C | 1 | 11% |
| Series D | 1 | 11% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 4 | 44% |
| Spain | 1 | 11% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| SANIFIT | SANIFIT is a biotechnology company focused on treatments for calcification disorders. | $60.6M | Series D | Jun 26, 2019 |  |
| Bionure | Bionure is a late-preclinical company focused at developing First-in-Class SGK agonists for the treatment of rare ophthalmology diseases. | $4.4M | Series A | May 17, 2018 |  |
| Carbylan Therapeutics | Carbylan Therapeutics was founded in 2004 with worldwide headquarters currently located in Palo Alto, California. They are a clinical-stage specialty pharmaceutical company focused on the development and commercialization of proprietary combination therapies. Our vision is to deliver best-in-class therapies to large growing markets where there is aclear unmet clinical need. | $6M |  | Jan 03, 2013 |  |
| PneumRx | PneumRx, Inc., a start-up medical device company, develops minimally invasive treatments for emphysema patients. The company develops RePneu Lung Volume Reduction Coil, an investigational device for treating emphysema patients. PneumRx, Inc. was founded in 2004 and is based in Mountain View, California. | $33M |  | Jan 04, 2011 |  |
| Carbylan Therapeutics | Carbylan Therapeutics was founded in 2004 with worldwide headquarters currently located in Palo Alto, California. They are a clinical-stage specialty pharmaceutical company focused on the development and commercialization of proprietary combination therapies. Our vision is to deliver best-in-class therapies to large growing markets where there is aclear unmet clinical need. | $20M | Series B | Nov 26, 2007 |  |
| PneumRx | PneumRx, Inc., a start-up medical device company, develops minimally invasive treatments for emphysema patients. The company develops RePneu Lung Volume Reduction Coil, an investigational device for treating emphysema patients. PneumRx, Inc. was founded in 2004 and is based in Mountain View, California. | $27M | Series B | Mar 06, 2007 |  |
| USGI Medical | USGI Medical develops technologies that enable incisionless procedures which help patients return to normal activities and lifestyles faster compared to traditional laparoscopic and open surgery.USGI’s Incisionless Operating Platform (IOP) provides surgeons the operating platform and specialized tools they need to perform surgery through apatient’s mouth or other natural orifices, reducing the need for external incisions into the abdomen. USGI has demonstrated the breakthrough capability to reliably and durably fixate and plicate GI tract tissue without an incision. Operating through the body’s natural orifices offers promise for less pain, shorter hospital stays, reduced risk of wound infection and no external scars – and is rapidly becoming an option demanded by patients and healthcare providers. | $21M | Series C | Jul 01, 2006 |  |
| USGI Medical | USGI Medical develops technologies that enable incisionless procedures which help patients return to normal activities and lifestyles faster compared to traditional laparoscopic and open surgery.USGI’s Incisionless Operating Platform (IOP) provides surgeons the operating platform and specialized tools they need to perform surgery through apatient’s mouth or other natural orifices, reducing the need for external incisions into the abdomen. USGI has demonstrated the breakthrough capability to reliably and durably fixate and plicate GI tract tissue without an incision. Operating through the body’s natural orifices offers promise for less pain, shorter hospital stays, reduced risk of wound infection and no external scars – and is rapidly becoming an option demanded by patients and healthcare providers. | $12M | Series B | Dec 15, 2003 |  |
| USGI Medical | USGI Medical develops technologies that enable incisionless procedures which help patients return to normal activities and lifestyles faster compared to traditional laparoscopic and open surgery.USGI’s Incisionless Operating Platform (IOP) provides surgeons the operating platform and specialized tools they need to perform surgery through apatient’s mouth or other natural orifices, reducing the need for external incisions into the abdomen. USGI has demonstrated the breakthrough capability to reliably and durably fixate and plicate GI tract tissue without an incision. Operating through the body’s natural orifices offers promise for less pain, shorter hospital stays, reduced risk of wound infection and no external scars – and is rapidly becoming an option demanded by patients and healthcare providers. | $3.5M | Series A | Dec 01, 2001 |  |

9 of 9 investments shown.

## Co-investors
- [Adams Street Partners](https://shizune.co/investors/profile/adams-street-partners) — VC Fund, 2 deals together
- [Forbion Capital Partners](https://shizune.co/investors/profile/forbion-capital-partners) — VC Fund, 2 deals together
- [InterWest Partners](https://shizune.co/investors/profile/interwest-partners) — VC Fund, 2 deals together
- [Spray Venture Partners](https://shizune.co/investors/profile/spray-venture-partners) — VC Fund, 2 deals together
- [Telegraph Hill Partners](https://shizune.co/investors/profile/telegraph-hill) — VC Fund, 2 deals together
- [Criteria Venture Tech](https://shizune.co/investors/profile/caixa-capital) — VC Fund, 1 deal together

## About Alta Life Sciences

VC Fund · Barcelona, Spain

Alta Life Sciences is a leading multistage venture capital investment firm. Alta LS will invest in companies at all stages of development: from seed financing through commercial growth. Alta LS invests in all areas of life sciences including biotechnology, medical devices, diagnostics, genomics and digital health.

5 contacts available at Alta Life Sciences.

| Name | Title | Profile |
| --- | --- | --- |
| Guy P. Nohra | Managing General Partner | https://shizune.co/investors/profile/guy-p-nohra |
| Scott Moonly | General Partner | https://shizune.co/investors/profile/scott-moonly |
| José Antonio Mesa | Partner | https://shizune.co/investors/profile/jos-antonio-mesa |
| Miguel Valls | General Partner | https://shizune.co/investors/profile/miguel-valls |
| Montserrat Vendrell | Partner | https://shizune.co/investors/profile/montserrat-vendrell |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Guy P. Nohra invest in?

Guy P. Nohra invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series B and Series A stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Guy P. Nohra last invest?

The most recent investment recorded for Guy P. Nohra closed in Jun 2019. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co